<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976622</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/55</org_study_id>
    <nct_id>NCT03976622</nct_id>
  </id_info>
  <brief_title>Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata</brief_title>
  <acronym>INFLAMMAVit</acronym>
  <official_title>Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a study of translational research with mechanistically objectives and including
      biological samples of patients with chronic inflammatory disorders
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a single-center prospective study to collect blood and skin tissue at the time
      of consultation with a patient with non-segmental vitiligo, psoriasis, atopic dermatitis or
      alopecia areata, in order to better understand and compare blood and skin immune response in
      chronic inflammatory skin disorders: psoriasis, alopecia areata, atopic dermatitis and
      vitiligo.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 3, 2019</start_date>
  <completion_date type="Anticipated">June 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the phenotype and function of blood and skin T-cell in chronic inflammatory skin disorders: psoriasis, vitiligo, atopic dermatitis, alopecia areata</measure>
    <time_frame>Day 1</time_frame>
    <description>Description of the phenotypic analysis of cutaneous T-cell and blood of vitiligo patients evaluated by flow cytometry</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Vitiligo</condition>
  <condition>Psoriasis</condition>
  <condition>Alopecia Areata</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>vitiligo</arm_group_label>
    <description>Patients aged 18 to 75 years with non-segmental vitiligo;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psoriasis</arm_group_label>
    <description>Patients aged 18 to 75 years with plaque psoriasis;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atopic dermatitis</arm_group_label>
    <description>Patients aged 18 to 75 years with atopic dermatitis;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alopecia areata</arm_group_label>
    <description>Patients aged 18 to 75 years with alopecia areata sclerosis;</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples: serum and PBMC</description>
    <arm_group_label>alopecia areata</arm_group_label>
    <arm_group_label>atopic dermatitis</arm_group_label>
    <arm_group_label>psoriasis</arm_group_label>
    <arm_group_label>vitiligo</arm_group_label>
    <other_name>Blood samples: serum and PBMC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Skin biopsies</intervention_name>
    <description>These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.</description>
    <arm_group_label>alopecia areata</arm_group_label>
    <arm_group_label>atopic dermatitis</arm_group_label>
    <arm_group_label>psoriasis</arm_group_label>
    <arm_group_label>vitiligo</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral mononuclear cells, Serum, paraffine-embedded/ frozen skin.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        450 patients (300 patients with vitiligo, 50 psoriasis patients, 50 patients with atopic
        dermatitis, 50 patients with alopecia areata)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 to 75 years;

          -  Patients with non-segmental vitiligo;

          -  Patients with plaque psoriasis;

          -  Patients with atopic dermatitis;

          -  Patients with alopecia areata sclerosis;

          -  written consent, free, informed and signed by the patient and the investigator (before
             any examination required by the study);

          -  Subject affiliated or beneficiary of a social security system.

        Exclusion Criteria:

          -  Patients with segmental vitiligo

          -  Patients under local treatment (topical corticosteroid-Calcineurin inhibitor) for less
             than two weeks.

          -  Patients on therapy, systemic treatments: acitretin, methotrexate, cyclosporine,
             Apremilast, infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab,
             dupilumab) for less than 4 weeks.

          -  Pregnant or breastfeeding women

          -  Patient (e) under guardianship

          -  Patient (e) Non-affiliated (e) a social protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien SENESCHAL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien SENESCHAL, MD,PhD</last_name>
    <phone>+335 56 79 49 63</phone>
    <email>julien.seneschal@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sitraka ANDRIAMIASY</last_name>
    <phone>+335.56.82.06.55</phone>
    <email>sitraka.andriamiasy@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Dermatologie - Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin inflammation</keyword>
  <keyword>Cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
    <mesh_term>Vitiligo</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

